AFT Pharmaceuticals posts $11 mln first-half loss after boosting R&D spend, launching OTC products

Fiona Rotherham
Wed, 23 Nov 2016

By Fiona Rotherham Nov. 24 (BusinessDesk) - AFT Pharmaceuticals, the Auckland-based drug-maker, widened its first-half loss to $11 million from $5.8 million after ramping up research and development and launching over-the-counter products in Australia and Singapore. The figures confirm a market trading update the company supplied earlier this month. Cash on hand dropped to $16 million from $28 million the previous year and the company said it had the financial flexibility to increase cash reserves with further drawn downs available on its...
Property
Tenancy law could turn good neighbourhoods into slums: landlords
Brent Melville | Thu, 06 Aug 2020

The new Residential Tenancies Amendment Bill 2020, which passed under urgency yesterday, got the balance right, placed reasonable requirements on both landlords and tenants and would endure through Ne...

Markets
MARKET OPEN: Kiwi holds its own as greenback falters, US equities push higher
Rebecca Howard | Thu, 06 Aug 2020

The kiwi dollar continues to hold its own as the greenback is weighed down by poor US data while the domestic share market may take cheer from a lift on Wall Street after positive earnings reports. ...

Listed Companies
Billion dollar hotel developments on backburner until better times
Brent Melville | Thu, 06 Aug 2020

Plans for at least 25 major hotel developments, valued at $2 billion, are gathering dust pending decisions on when, or if, construction will commence in the wake of border closures. The two dozen o...

Partner content
Don’t fear the robots. How software can help your business succeed

New Zealand businesses are on the road to recovery from the economic impact of the Covid-19 crisis but they, like corporates around the world, are having to change their operational practices.